Results 171 to 180 of about 128,122 (265)

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons   +11 more
wiley   +1 more source

Short- and Long-Term Outcomes of Pancreatic ERCP in Pre-Teens: A Swedish Single Center Study. [PDF]

open access: yesJ Clin Med
Scandavini CM   +8 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry   +4 more
wiley   +1 more source

Air Everywhere: A Rare Post-ERCP Syndrome of Acute Pancreatitis, Pneumothorax, and Multicompartment Air Leak without Perforation. [PDF]

open access: yesClin Med Insights Case Rep
Hazzouri AA   +6 more
europepmc   +1 more source

Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Helena W. Rodbard   +7 more
wiley   +1 more source

The emerging role of the Hippo signaling pathway in interorgan crosstalk

open access: yesThe FEBS Journal, EarlyView.
Hippo signaling functions as a central hub of interorgan communication. Systemic cues from the gut, adipose tissue, and skeletal muscle—including hormones, metabolites, and microbial signals—regulate YAP/TAZ activity in a tissue‐ and context‐dependent manner.
Gahyeon Song   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy